Does continuous renal replacement therapy favourably influence the outcome of the patients? by Jakob, S. M. et al.
Nephrol Dial Transplant (1996) 11: 1250-1255
Dialysis News
Nephrology
Dialysis
Transplantation
Does continuous renal replacement therapy favourably influence the
outcome of the patients?
S. M. Jakob, F. J. Frey and D. E. Uehlinger
Division of Nephrology, Department of Medicine, University of Berne, Inselspital, CH-3010 Berne, Switzerland
Abstract Continuous haemodialysis and continuous
haemofiltration are efficient and safe techniques for
the treatment of acute renal failure. Theoretical advant-
ages are improved haemodynamic stability and easier
fluid removal. All 15 available studies comparing inter-
mittent (522 patients) with continuous (651 patients)
renal replacement therapy have been reviewed. From
these studies it cannot be established, whether the use
of a continuous instead of an intermittent treatment
modality improves the outcome in patients with acute
renal failure. Reviewing all 67 published studies dealing
with continuous renal replacement therapy revealed a
trend to a decreasing mortality rate (/><0.08) over the
last 11 years, whereas the mean age and the severity
of illness of the patients, measured by the APACHE
II score, did not change. In order to establish whether
the quality of treatment has improved as a function of
time, two quality factors (QF) were created, i.e. QF
for age (mean age/mean mortality rate of the patients
treated) and QF for severity of diseases (mean
APACHE II/mean mortality rate). Both QF improved
from 1984 until 1994, when analyzed for continuous
(P< 0.001) or intermittent (P< 0.001) treatment mod-
ality. Thus the quality of treatment of patients with
acute renal failure improved during the last decade.
However, there is no evidence with respect to survival
rate that a continuous renal replacement therapy is
superior to an intermittent one.
Key words: acute renal failure; continuous haemodia-
lysis; continuous haemofiltration; mortality
Introduction
Since the introduction of continuous haemofiltration
[1] and continuous haemodialysis [2], these techniques
with several modifications have turned out to be effi-
cient and save [3-5]. Despite the theoretical advantages
of continuous forms of renal replacement therapy
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(RRT), such as improved haemodynamics [6], easier
fluid removal [6,7] and greater flexibility with paren-
teral nutrition [7], continuous therapies might have
some drawbacks: if the coagulation parameters in the
patient are normal and a reasonable life-span of the
filter has to be obtained, anticoagulation is compulsory.
Possibly, there is an increased frequency of access
related complications [3]. Furthermore, once very
simple and possibly the cheapest form of RRT, todays
continuous methods include highly sophisticated treat-
ment devices to guarantee treatment safety and are
thought to be some 2.5 times more expensive than
conventional intermittent dialysis and/or haemofiltra-
tion [8,9]. This difference might even be more pro-
nounced if one considers the additional manpower
required. Thus, in order to be cost effective morbidity
and mortality of patients with acute renal failure
(ARF) should be better when a continuous instead of
an intermittent RRT is applied.
Although there is some evidence that slow continu-
ous techniques in comparison with conventional (inter-
mittent) RRT might improve morbidity and mortality
of patients with ARF [10-12], prospective controlled
trials comparing the different forms of RRT have not
been performed.
This review tries to establish first whether differences
in outcome are observed between continuous and inter-
mittent treatment modalities and second, whether an
improvement in the outcome of patients with acute
renal failure treated with continuous modalities of dia-
lysis and ultrafiltration techniques occurred during the
last 10 years. For that purpose all peer-reviewed publica-
tions of trials concerning the use of continuous forms
of RRT with or without an intermittently treated control
group were analysed. Studies available only as an
abstract were not considered for the subsequent analysis.
Studies comparing continuous with intermittent
forms of renal replacement therapy
Fifteen studies comparing intermittent (522 patients)
with continuous (651 patients) forms of RRT have
been published (Table 1). Whereas most studies
reported observations from patient numbers between
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Table. 1. Studies comparing intermittent with continuous renal replacement therapies
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Author, year Number
of
patients
Mean age
age
(years)
MAP
(mmHg)
APACHE
II
Fluid
allowance
(I/day)
Renal
recovery
Mortality Study
characteristics
Filter
Mauritz, 1986 [8] 58 50 uk uk uk 34 81 re.nr
-HD 22 52 27 91 CDAK
-CAVH 9 51 11 89 AMICON
- C W H 27 47 48 70 AMICON
Bartlett, 1986 [16] 56 57 uk 21 uk uk 79 re
-HD 24 56 21 88 C-Acetate
-CAVH 32 59 21 72 AMICON
Simpson, 1987 [7] 32 50 uk 18 uk uk 60 re.nr
-cont UF/Dial. 14 48 17 50 F40/F60
-HD 18 52 18 67 Cuprophan
Paganini, 1988 [3] 142 62 75 31 3.2 17 79 re.nr
-continuous 27 65 65 36 3.8 19 81 uk
-intermittent 47 62 87 27 2.1 19 82 uk
-combined 68 60 71 31 3.8 15 76 uk
Maher, 1989 [18] 90 51 uk uk uk 73 re,nr
-CAVH (ev. +IHD) 65 26 FH55
-CAVHD 22 26 AN69
-HD 3 27 uk
Favre, 1989 [19] 76 uk 88 uk uk uk uk re,nr uk
- C W H 40 79
-HD 36 98
Davenport, 1991 [15] 22 uk uk uk uk uk uk p,pr
HD FH77
CAVH/CAVHD Hosp2400
Bosworth, 1991 [13] 320 60 79 26 uk uk 68 re.nr Polyamid/
-continuous 95 70 82 Polyacnitr
-HD 138 85 60 Cuprophan
-combined 87 79 76 as above
Bastien, 1991 [12] 66 57 22 uk uk 62 p,nr
-HD 32 54 20 75 uk
-CVVHD 34 60 75 23 50 AN69
Kierdorf, 1991 [11] 146 uk uk uk uk uk 86 re uk
- C W H F 73 78
-HD 73 93
McDonald, 1991 [17] 42 46 uk uk uk uk 79 re
-HD 10 50 70 Cuprophane
-CAVHD 22 45 70 AN69S
-HD/CAVHD 10 44 80 as above
Bellomo, 1993 [4] 167 58 uk 27 uk uk 65 re,nr
-CHDF 83 60 28 59 AN69S
-CD 84 56 26 70 Cuprophan
Bellomo, 1993 [5] 160 59 uk 27 uk uk 65 re + p,nr
-CHDF 76 62 29 59 AN69S
-CD 84 56 26 71 Cuprophan
Kruczynski 1993 [10] 35 56 uk 27 uk uk 55 re,nr
-CAVH 12 45 26 25 Gambro
-HD 23 61 28 82 F6/F60
Davenport 1993 [14] 32 33 77 26 uk uk uk p,pr
-HF 12 33 82 22 FH77
-CAVH/CAVHD 20 33 74 28 Hosp2400
HD, Intermittent haemodialysis, r, Randomization, CAVH, Continuous arteriovenous haemofiltration, pr, Partly randomized, C W H ,
Continuous venovenous haemofiltration, nr, No randomization, CHDF, Continuous haemodiafiltration, re, Retrospective, CD, Conventional
dialysis (intermittent haemodialysis or acute peritoneal dialysis), p, Prospective, HF, Intermittent haemofiltration, uk, Unknown, CHF,
Continuous haemofiltration, cont UF/Dial., Continuous haemodialysis with ultrafiltration, CAVHD, Continuous arteriovenous haemofiltra-
tion with dialysis, MAP, Mean arterial presure.
3 and 36 (intermittently treated groups) and 9-87
(continuously treated groups) respectively, there are
some studies with more than a 100 patients [3-5,11,13].
Only four trials were carried out prospectively
[5,12,14,15] and there is no published prospective trial
with complete randomization available.
The type of filter used was indicated in 12 investi-
gations [4,5,7,8,10,12-18]. No study applied filters
with the same material for the continuously and inter-
mittently treated patients. Intermittent treatments
were mainly carried out with cellulose-based filters
[4,5,7,8,13,16,17], whereas continuous forms of RRT
were performed by polyacrylonitrile [4,5,12-15,17,18],
polysulphone [7,18] or polyamide [13] filters.
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The mean age of the patients was indicated in all
but three studies [11,15,19] and ranged from 46 to 62
years. In only one study young patients (mean age 33
years) with a head injury were treated [14].
Results about mean arterial pressure were reported
in only four of 15 publications [3,13,14,19]. These
values were higher in all studies in the intermittent
(88 + 7 mmHg, mean + SD) than in the continuous
(72 + 6 mmHg) groups (P<0.05; Wilcoxon signed rank
test). This suggests that patients with low blood pres-
sure and presumably haemodynamic instability were
preferentially treated by a continuous dialysis modality.
APACHE II scores were reported in 10 studies
[3-5,7,10,12-14,16,18] and the mean values ranged
from 18 to 31. Two studies were excluded from further
analysis [13,18]. One study reported only a mean
APACHE II score for the whole study population [13]
and the other study was incomplete with respect to the
APACHE II scores [18].
Fluid allowance, often considered to be a criterion
for choosing a continuous form of RRT was given in
only one report [3]; it was higher in the continuously
than in the intermittently treated group (3.8 vs 2.1
I/day).
Two therapeutic end-points were given, renal
recovery [3,8] and mortality [3-5,7,8,10-13,16-18]
(Table 1). Renal recovery was reported in two studies
[3,8]. In none of them was a definition of renal recovery
given. As a consequence of the paucity of results, no
definite conclusion about the superiority of the method
of RRT with respect to renal recovery can be made
(Table 1). Mortality rate is known from 12 of 15
studies (Table 1). The values for mortality rate ranged
between 55 and 86%. In three investigations a statistic-
ally significantly lower mortality was found in continu-
ously than in intermittently treated patients [10-12].
A similar difference was detected in a subgroup of
patients from a further study [4].
Despite the non-randomized character of most stud-
ies and the many historical control groups (Table 1)
for intermittent therapy all available studies
[3-5,7,8,10-19] were pooled for further analysis.
Weighted multivariate logistic regression analysis was
used to examine the influence of APACHE II score,
patient age and investigation year on patient mortality
in the reviewed trials. Weighted least-squares minimiza-
tion was done by weighting the loss function with
N*q*(l —q) [20], where N is the number of subjects
in each pooled study and q is the reported gross
mortality rate of the corresponding study. Dummy
variables were introduced to test for possible differ-
ences between treatment modalities in the relationship
of patient mortality and the above-mentioned inde-
pendent variables [20].
Pooling all the patients from the published trials
revealed a mean age of 58 + 7.1 years in patients with
ARF on intensive care units, a mean APACHE II
score of 27+4.9 and a mean mortality rate of 69%. In
Figure 1 the results are given separately for the years
1986, 1987, 1988, 1991 and 1993. For the other years
no studies were available. The analysis of Figure 1
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Fig. 1. Comparison of mortality rates, mean age and APACHE II
scores between intermittently (hatched bars) and continuously (open
bars) treated patients with ARF. The values were derived from
studies published in 1986, 1987, 1988, 1991 or 1993. N indicates the
number of patients analysed. In the upper part of the figure quality
factors of treatment are shown. When age ( - • - , intermittently
treated patients; -D- , continuously treated patients) or APACHE
II ( - • - , intermittently treated patients; - O - , continuously treated
patients) were considered for the calculation of the quality factors
(QF) the values increased with time (/><0.001).
shows a slightly decreasing mortality rate from 80% in
1986 to 64% in 1993 when intermittently and continu-
ously treated patients were considered as a group.
Logistic regression analysis, controlled for age,
APACHE II score, observation year, and treatment
modality, revealed a trend for a better outcome in
recent years, independent of treatment modality
(P<0.07). However, no differences in mortality rates,
APACHE II scores or mean age were detected between
intermittent and continuous forms of RRT.
In order to establish whether the quality of treatment
of patients with ARF increased in recent years one has
to consider both, the severity of the underlying disease
states and the mortality rates. The severity of the
underlying disease, i.e. the likelihood of not surviving
correlates with age and the APACHE II score [21].
Thus dividing age or APACHE II score by mortality
rate provides a measure of quality of the treatment. In
Figure 1 (upper part) we propose numerical values for
such quality factors. For that purpose the weighted
mean values of age and APACHE II score respectively,
were divided by the corresponding weighted mean
values of mortality. High values of those indices suggest
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good treatment quality whereas low values suggest the
opposite. In Figure 1 the mean values from all studies
from where such indices could be derived, are given
(1986, 2 studies; 1987, 1 study; 1988, 2 studies; 1991,
5 studies; 1993, 4 studies). When analysed as a function
of the year, treatment quality improved (P< 0.001,
weighted logistic regression analysis) as can be clearly
shown by the steadily increasing quality factors
(Figure 1).
Studies reporting patients on a continuous form of
renal replacement therapy without a control group
An additional 52 studies describing only patients
treated with continuous RRT without an intermittently
treated control group were found in the literature
[2,6,9,22-70]. The number of patients included in the
reported studies ranged from five [23] to 255 [70]
patients. The total number of patients reported in these
52 publications was 1860.
Treatment modalities included continuous haemo-
filtration, either arteriovenous [23,26,28-32,37,45,-
46,50-53,59], venovenous [36,38,47,49,60,66] or
both[34,35,44,55], slow continuous ultrafiltration
[6], continuous haemodialysis, either arterio-
venous[39,41,54,56,58,61,65,68], venovenous [25,31]
or both [9,24,42,62,63], continuous haemodiafiltration
[40,48,67,69] as well as both continuous arteriovenous
haemofiltration and haemodialysis[43,57] respectively.
In one study continuous RRT was combined with
intermittent haemodialysis [29].
The types of niters used were mostly polyacrylonitrile
[9,24,25,28,31,33-35,37-42,48,53,58,61,65,66,68-70],
but also polysulphone [6,23,26,30,31,36,43,49-51,57]
or polyamide [32,44,46,47,51,55,56,58,70] niters have
been used. In some studies the type of filter prescribed
was not indicated.
Values for mean age are available from all but three
trials [37,45,63] and ranged between 38 years [62] and
73 years [41]. Mean APACHE II scores were available
from 12 studies only [9,24,25,33-35,39,58,59,61,64,66].
The reported values were between 21 [46,59] and 33
[39]. Mortality rates were given in all but six
[43,45,52,56,57,59] publications. These values ranged
from 44% [31] to 100% [50].
Data from the 52 studies without a control group
were pooled together with data from the continuous
groups of the 15 studies with a control group discussed
above (Table 1) in order to analyse the influence of
patient age, APACHE II score and investigation year
on patient mortality using the same logistic regression
analysis as described above. When the mortality rate
was analysed as a function of the year a trend to a
steady decline was observed (/><0.08) (Figure 2). The
APACHE II scores and the mean age of the patients
did not change during the observation period. However
the above defined quality factors of treatment increased
as a function of time (Figure 2). For the calculation
of these quality factors the following number of studies
(year) could be considered: For the quality factor
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Fig. 2. Mortality rates, mean age and APACHE II scores from 1984
to 1994. Included are all published studies about treatment with a
continuous modality of renal replacement therapy (number of
patients: 2511). There is a trend to lower mortality rates in recent
years, whereas mean age and APACHE II scores did not change. In
the upper part of the figure the quality factors (QF) of treatment
are shown. When considering age ( - • - ) or APACHE II scores
( - • - ) for the calculation of the quality factor a steady increase with
time (P< 0.001) was observed for both parameters.
derived from mean age and mortality 16 (1991), 11
(1993), 8 (1988), 5 (1992), 4 (1989), 3 (1984, 1987),
2 (1986, 1994), 1 (1985), 0 (1990) and for the quality
factor derived from mean APACHE II scores and
mortality 7 (1993), 3 (1988, 1991, 1992), 2 (1989), 1
(1986, 1987), 0 (1984, 1985, 1990, 1994) respectively.
Conclusions
There is a steadily increasing pressure on the medical
community in the western world to demonstrate
improving quality of patient treatment. With respect
to the treatment of ARF the difficulty to prove unequi-
vocally a decreasing mortality rate over the last decade
might be due to methodological problems, because the
number of patients treated within a centre was rela-
tively small, the case mix was heterogenous, and the
treatment modality as well as the experience of the
care providers changed as a function of time. As shown
in the present review, a meta-analysis cannot be per-
formed since not enough information about the various
studies is available. In an attempt to get some qualitat-
ive information about the changes in the outcome all
available studies using continuous forms of RRT have
been pooled and the outcome analysed. This approach
cannot exclude a publication bias and therefore the
results have to be interpreted carefully. Within the
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limitations of this approach one can conclude that the
quality of treatment improved as a function of time
when the outcome determinants age and APACHE II
score are used to correct for the changing patient
population.
In a recent editorial about continuous and intermit-
tent haemodialysis for acute renal failure on the intens-
ive care unit Van Bommel [71] concluded that final
proof for the superiority of continuous blood purifica-
tion techniques to improve outcome in ARF has not
been provided until now. That conclusion is supported
by the detailed analysis of the literature presented in
this paper. It is reassuring how many comparative
trials have been performed in that field; however, it is
surprising how incomplete these studies are when ran-
domization, description of the patient population
investigated, and assessement of therapeutic end-points
are considered (Table 1). Furthermore, economic end-
points have virtually never been assessed in these
studies. If in the future no advantage for the patients
with respect to survival rate can be found when a
continuous instead of an intermittent RRT is used, the
sum of expenditures for material and labour might
ultimately be pivotal for choosing the type of RRT.
Thus, future studies designed to investigate the impact
of the treatment modality on patient survival rate
should comprise an economic assessement.
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